# Co-prescribing benzodiazepines and opioids in oncology patients: disease burden, patient characteristics, and safety - URL: https://alisanburak.com/en/wcp-2026-posterler/ev1096 - Language: en - Last updated: not specified - Page title: Co-prescribing benzodiazepines and opioids in oncology patients: disease burden, patient characteristics, and safety | WCP 2026 Summary > Following a brief team training and action alert intervention, the rate of naloxone prescribing and overdose education among patients receiving both opioids an… This page was translated automatically from Turkish. [Read the original](https://alisanburak.com/wcp-2026-posterler/ev1096) This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it. EV1096 E-PosterPsychopharmacologyRetrospective chart review and pre–post intervention evaluation # Co-prescribing benzodiazepines and opioids in oncology patients: disease burden, patient characteristics, and safety CO-PRESCRIPTION OF BENZODIAZEPINES AND OPIOIDS IN ONCOLOGY PATIENTS: DISEASE BURDEN, PATIENT TYPE, AND SAFETY Presenter: William C. Jackson Country: United States of America Institution: West Cancer Center and Research Institute, Palliative Care Division Following a brief team training and action alert intervention, the rate of naloxone prescribing and overdose education among patients receiving both opioids and benzodiazepines increased from 64% to 94%. The study aimed to evaluate co-prescription of opioids and benzodiazepines (COB), improve naloxone provision and overdose education, and compare the characteristics of patients receiving and not receiving COB. Palliative care visits at an outpatient cancer center were retrospectively reviewed; 464 eligible patients were evaluated before the intervention and 530 afterward. The intervention consisted of team training and action alerts sent via secure email over 90 days. Before the intervention, co-prescribing was identified in 53/464 patients (11.2%), of whom 34 (64%) received naloxone and overdose education; after the intervention, co-prescribing was identified in 68/530 patients (12.8%), of whom 64 (94%) received naloxone and overdose education. In a secondary analysis comparing 873 patients not receiving COB with 121 patients receiving COB, the mean age was 60.4 versus 57.7 years (p=0.03), the proportion of White patients was 44% versus 74% (p<0.05), the proportion of women was 60% versus 74% (p<0.01), the proportion with active cancer was 74% versus 70% (p=0.40), the mean morphine equivalent daily dose (MEDD) was 88 versus 108 (p=0.06), and the proportion with a mental disorder diagnosis was 49% versus 100% (p<0.01). A chart comparing the findings with published studies showed a co-prescribing rate of 12.2% among cancer patients receiving palliative care at this center. The study concluded that although co-prescribing is sometimes necessary for palliative symptom relief, these patients should receive overdose education and naloxone, and that brief clinical training and action alerts are effective and efficient tools for improving these safety practices. The authors emphasized that variation in prescribing patterns among patients with different demographic characteristics warrants further investigation. [View the original poster](https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1392) How to cite this study APA 7: Jackson, W. C., et al. (2026, September 23-26). Co-prescription of benzodiazepines and opioids in oncology patients: disease burden, patient type, and safety [E-poster]. 26th WPA World Congress of Psychiatry (WCP 2026), Stockholm, Sweden. https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1392 Vancouver: Jackson WC, et al. Co-prescription of benzodiazepines and opioids in oncology patients: disease burden, patient type, and safety [e-poster]. 26th WPA World Congress of Psychiatry (WCP 2026); 2026 Sep 23-26; Stockholm, Sweden. Available from: https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1392 Author names and title formatting were generated automatically from the congress system; please check them against the original poster before use. ## On the same topic - [Açığı kapatmak: erişkin DEHB ilacı başlanmadan önce EKG sevk uyumunun iyileştirilmesi, kapalı döngü klinik denetim](https://alisanburak.com/en/wcp-2026-posterler/ev0088) - [Anksiyete bozukluğu olan hastalarda psikobiyotik müdahalesi: ısıl işlem görmüş Lactobacillus paracasei PS23'ün etkilerini inceleyen çift kör randomize kontrollü çalışma](https://alisanburak.com/en/wcp-2026-posterler/ev0126) - [Otizm spektrum bozukluğunda bumetanidin tedavi edici potansiyeli: güncel kanıtlar ve gelecek yönelimleri](https://alisanburak.com/en/wcp-2026-posterler/ev0157) - [Verbaskozid ile otizm spektrum bozukluğu tedavisinin mekanizmaları: ağ farmakolojisi, moleküler yerleştirme ve moleküler dinamik temelli inceleme](https://alisanburak.com/en/wcp-2026-posterler/ev0172) - [Otizm spektrum bozukluğunun çekirdek belirtilerinin tedavisinde kannabidiol: sistematik derleme](https://alisanburak.com/en/wcp-2026-posterler/ev0186) [All WCP 2026 summaries](https://alisanburak.com/en/wcp-2026-posterler) --- Kaynak / Source: https://alisanburak.com/en/wcp-2026-posterler/ev1096 İletişim / Contact: Bağdat Caddesi, Veli Güneysu Apt. No:453 K:4 D:9, Suadiye / Kadıköy, İstanbul · +90 532 642 95 25 · info@alisanburak.com · https://alisanburak.com/bagdat-caddesi-psikoterapi-iletisim